For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized ...

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights how the ...

A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, ...

Study reveals VLCFA metabolism as a key target in multiple myeloma, enhancing drug efficacy and overcoming resistance.

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...

China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...

Panelists discuss how to navigate and choose among multiple guideline-recommended induction regimens for patients with ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...